158. 結節性硬化症 Tuberous sclerosis Clinical trials / Disease details
臨床試験数 : 108 / 薬物数 : 67 - (DrugBank : 17) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
Showing 1 to 10 of 108 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05252585 (ClinicalTrials.gov) | May 31, 2022 | 16/2/2022 | A Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) A Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis ComplexWh ... | Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese A ... | Renal Angiomyolipoma | Drug: Everolimus | Novartis Pharmaceuticals | NULL | Not yet recruiting | 20 Years | 65 Years | All | 10 | Phase 4 | NULL |
| 2 | NCT05059327 (ClinicalTrials.gov) | November 22, 2021 | 20/8/2021 | Basimglurant in Children and Adolescents With TSC | A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children and Adolescents With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-control ... | Tuberous Sclerosis Complex | Drug: Basimglurant with crossover to Placebo;Drug: Placebo with crossover to Basimglurant | Noema Pharma AG | NULL | Not yet recruiting | 5 Years | 18 Years | All | 55 | Phase 2 | NULL |
| 3 | NCT05104983 (ClinicalTrials.gov) | October 13, 2021 | 22/10/2021 | Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Tuberous Sclerosis Complex;Epilepsy | Drug: Sirolimus;Drug: Placebo | Darcy Krueger | NULL | Recruiting | N/A | 6 Months | All | 64 | Phase 2 | United States |
| 4 | NCT05044819 (ClinicalTrials.gov) | July 7, 2021 | 30/8/2021 | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol ... | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated Wi ... | Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex | Drug: Cannabidiol | GW Research Ltd | NULL | Recruiting | 1 Year | N/A | All | 150 | Phase 4 | United States |
| 5 | NCT04485104 (ClinicalTrials.gov) | May 19, 2021 | 21/7/2020 | Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiseizure Medication, in Participants Age 1 Month to <12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solutio ... | An Open-label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) Compared With Standard of Care Antiseizure Medication, in Patients Age 1 Month to Less Than 12 Months of Age With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures An Open-label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of ... | Seizure in Participants With Tuberous Sclerosis Complex | Drug: GWP42003-P;Drug: SOC | GW Research Ltd | NULL | Recruiting | 1 Month | 11 Months | All | 12 | Phase 3 | United States |
| 6 | ChiCTR2000039523 | 2020-12-01 | 2020-10-30 | Safety and efficacy of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis: a case series study Safety and efficacy of everolimus in patients with renal angiomyolipoma associated with tuberous scl ... | Safety and efficacy of Everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis: a case series study Safety and efficacy of Everolimus in patients with renal angiomyolipoma associated with tuberous scl ... | tuberous sclerosis complex;LD2D.2 | case series:everolimus; | Department of Pharmacy, Peking University First Hospita | NULL | Recruiting | 0 | 100 | Both | case series:20; | Phase 4 | China |
| 7 | NCT02860494 (ClinicalTrials.gov) | December 2020 | 4/8/2016 | Topical Everolimus in Patients With Tuberous Sclerosis Complex | Topical Everolimus Versus Placebo for the Treatment of Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. A Phase II/III, Multicentre, Randomized, Double-blind, Placebo-controlled Study of 3 Doses of Topical Everolimus. Topical Everolimus Versus Placebo for the Treatment of Facial Angiofibromas in Patients With Tuberou ... | Facial Angiofibromas | Drug: Everolimus;Drug: Placebo | Hospices Civils de Lyon | NULL | Withdrawn | N/A | 2 Years | All | 0 | Phase 2/Phase 3 | France |
| 8 | NCT04595513 (ClinicalTrials.gov) | September 8, 2020 | 6/10/2020 | Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants | Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants | Tuberous Sclerosis Complex;Epilepsy | Drug: TAVT-18 (sirolimus) | Children's Hospital Medical Center, Cincinnati | NULL | Active, not recruiting | N/A | 6 Months | All | 5 | Phase 1/Phase 2 | United States |
| 9 | ChiCTR2000031984 | 2020-05-01 | 2020-04-17 | Sirolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex and Epilepsy | Sirolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex and Epilepsy | Tuberous sclerosis complex; Epilepsy | experimental group:Antiepileptic drug + sirolimus;control group:antiepileptic drugs; | West China Hospital, Sichuan University | NULL | Pending | Both | experimental group:31;control group:31; | N/A | China | ||
| 10 | NCT04285346 (ClinicalTrials.gov) | April 8, 2020 | 18/2/2020 | Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) | A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B) A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis ... | Tuberous Sclerosis | Drug: Ganaxolone | Marinus Pharmaceuticals | NULL | Active, not recruiting | 2 Years | 65 Years | All | 24 | Phase 2 | United States |